Adipotide vs Semaglutide
How Adipotide and Semaglutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Adipotide and Semaglutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Adipotide vs Semaglutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Adipotide | Semaglutide |
|---|---|---|
| What it is | Prohibitin-targeting proapoptotic peptidomimetic | GLP-1 receptor agonist (a synthetic analog of the human gut hormone glucagon-like peptide-1) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Animal-only · Mixed · none in humans | Human RCT · Helped |
| Studied / approved for | Obesity and white-adipose-tissue reduction; Metastatic prostate cancer in men with obesity (terminated Phase 1 study) | Type 2 diabetes (blood-sugar control); Chronic weight management in obesity or overweight; Cardiovascular risk reduction |
| US regulatory status (2026) | research use only (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Type 2 diabetes (Ozempic, Rybelsus), Chronic weight management (Wegovy), Cardiovascular risk reduction |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 716 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Adipotide has no published human safety results. In monkeys, the principal toxicity was dose-dependent injury and altered function in the kidney's proximal tubules, including elevated creatinine and degenerative or necrotic tubular lesions. Most changes improved during recovery, but the human dose at which kidney injury begins is unknown. | Semaglutide is one of the most-studied peptides in humans, so its risks are well characterized rather than guessed at. The common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually worst during dose increases. Less common but serious concerns include pancreatitis and gallbladder disease, and the label carries a boxed warning about thyroid C-cell tumors seen in rodents, which is why it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Adipotide vs Semaglutide: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want the option with more human evidence behind it
Leans toward Semaglutide
Semaglutide's evidence sits at human rct, a more human tier than Adipotide's animal-only. That reflects how the data was gathered, not a guarantee it works.
If you want an FDA-approved, prescribable option
Leans toward Semaglutide
Semaglutide is FDA-approved (as of Jul 2026); Adipotide is research use only in the US, so it isn't available as an approved prescription.
References
- 1.Barnhart et al., 2011 — adipotide in obese monkeys (PMID 22072637)
- 2.ClinicalTrials.gov — Prohibitin-TP01 Phase 1 study (NCT01262664)
- 3.NCI Drug Dictionary — prohibitin-targeting peptide 1
- 4.PubChem — Adipotide (CID 163360068)
- 5.FDA — Bulk Drug Substances Used in Compounding
- 6.WADA — 2026 Prohibited List